Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:KALA NASDAQ:MTVA NASDAQ:PRLD NASDAQ:XCUR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeKALAKALA BIO$7.38+3.1%$5.52$2.92▼$11.20$46.20M-1.81187,641 shs108,492 shsMTVAMetaVia$0.63-1.0%$0.67$0.56▼$4.32$12.47M0.26176,521 shs60,783 shsPRLDPrelude Therapeutics$0.86+0.1%$0.88$0.61▼$6.80$48.39M1.22121,844 shs60,874 shsXCURExicure$7.45+1.2%$7.68$1.44▼$36.00$46.50M3.6790,145 shs154,198 shsBeginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceKALAKALA BIO+3.07%-1.60%+17.14%+115.79%+23.83%MTVAMetaVia-1.01%+3.43%-8.84%-11.29%+62,989,900.00%PRLDPrelude Therapeutics+0.06%+3.53%-1.99%+9.80%-83.19%XCURExicure+1.22%+5.67%+4.78%-34.88%+1,357.93%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationKALAKALA BIO3.9251 of 5 stars3.52.00.04.42.80.80.6MTVAMetaVia2.4271 of 5 stars3.50.00.00.03.20.01.3PRLDPrelude Therapeutics3.3136 of 5 stars3.54.00.00.00.03.30.6XCURExicure0.8853 of 5 stars0.02.00.04.71.70.80.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceKALAKALA BIO 3.00Buy$13.0076.15% UpsideMTVAMetaVia 3.00Buy$7.501,090.67% UpsidePRLDPrelude Therapeutics 3.00Buy$4.50424.78% UpsideXCURExicure 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest MTVA, PRLD, XCUR, and KALA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/11/2025KALAKALA BIOLADENBURG THALM/SH SHSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$12.006/2/2025KALAKALA BIOOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$15.005/23/2025KALAKALA BIOHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$15.00 ➝ $12.005/19/2025MTVAMetaViaMaxim GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$6.00 ➝ $3.00(Data available from 8/9/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookKALAKALA BIO$3.89M12.24N/AN/A$2.02 per share3.65MTVAMetaViaN/AN/AN/AN/A$0.92 per shareN/APRLDPrelude Therapeutics$7M6.92N/AN/A$2.39 per share0.36XCURExicure$500K94.17N/AN/A$1.12 per share6.65Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateKALAKALA BIO-$38.51M-$8.24N/AN/AN/AN/A-369.29%-64.99%N/AMTVAMetaVia-$27.59MN/A0.00N/AN/AN/A-219.57%-109.78%N/APRLDPrelude Therapeutics-$127.17M-$1.69N/AN/AN/AN/A-89.18%-69.26%8/11/2025 (Estimated)XCURExicure-$9.70M-$3.82N/A∞N/AN/A-219.60%-82.03%8/12/2025 (Estimated)Latest MTVA, PRLD, XCUR, and KALA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/11/2025Q2 2025PRLDPrelude Therapeutics-$0.45N/AN/AN/AN/AN/A8/8/2025Q2 2025KALAKALA BIO-$1.82-$1.71+$0.11-$1.71N/AN/A8/8/2025Q2 2025XCURExicureN/A-$0.41N/A-$0.41N/AN/A8/7/2025Q2 2025MTVAMetaVia-$0.32-$0.26+$0.06-$0.26N/AN/A6/27/2025Q1 2025XCURExicureN/A-$0.45N/A$0.49N/AN/A5/14/2025Q1 2025MTVAMetaVia-$0.57-$0.36+$0.21-$0.36N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthKALAKALA BION/AN/AN/AN/AN/AMTVAMetaViaN/AN/AN/AN/AN/APRLDPrelude TherapeuticsN/AN/AN/AN/AN/AXCURExicureN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioKALAKALA BIO3.191.991.99MTVAMetaViaN/A1.551.55PRLDPrelude TherapeuticsN/A5.185.18XCURExicureN/A2.912.91Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipKALAKALA BIO24.61%MTVAMetaVia1.37%PRLDPrelude Therapeutics79.72%XCURExicure42.82%Insider OwnershipCompanyInsider OwnershipKALAKALA BIO8.32%MTVAMetaVia0.80%PRLDPrelude Therapeutics63.90%XCURExicure3.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableKALAKALA BIO306.45 million5.92 millionNot OptionableMTVAMetaVia819.59 million19.43 millionN/APRLDPrelude Therapeutics12056.46 million20.38 millionOptionableXCURExicure506.32 million6.07 millionNot OptionableMTVA, PRLD, XCUR, and KALA HeadlinesRecent News About These CompaniesExicure Posts Wider Loss in Fiscal Q2August 8 at 8:13 PM | aol.comAExicure, Inc. Reports Second Quarter 2025 Financial Results | XCUR Stock NewsAugust 8 at 5:16 PM | gurufocus.comExicure, Inc. Reports Second Quarter 2025 Financial ResultsAugust 8 at 4:01 PM | businesswire.comExicure, Inc. (Nasdaq: XCUR) Regains Compliance with Nasdaq Filing RequirementsAugust 4, 2025 | businesswire.comShort Interest in Exicure, Inc. (NASDAQ:XCUR) Increases By 417.4%August 4, 2025 | americanbankingnews.comStocks to Watch: Exicure, TTECAugust 3, 2025 | marketwatch.comExicure Completes the Last Patient, Last Visit in Phase 2 Study of GPC-100 for Stem Cell Mobilization in Multiple Myeloma Patients Undergoing Autologous TransplantAugust 1, 2025 | businesswire.comXCUR | Exicure Inc. Annual Cash Flow Statement - MarketWatchJuly 19, 2025 | marketwatch.comIs Exicure Stock (XCUR) Experiencing a Dead Cat Bounce?June 30, 2025 | msn.comExicure Shares Up After Swing to Profit in 1QJune 27, 2025 | marketwatch.comExicure, Inc. Reports First Quarter 2025 Financial ResultsJune 27, 2025 | businesswire.comExicure, Inc. Received Nasdaq Delinquency Notice on Late Filing of its Form 10-QMay 28, 2025 | businesswire.comWhy Exicure Inc. (XCUR) Soared on MondayApril 22, 2025 | msn.comExicure’s subsidiary, GPCR Therapeutics doses 19th patient in its phase 2 study of GPC-100 in multiple myelomaApril 16, 2025 | pharmabiz.comPExicure to initiate new clinical trial in acute myeloid leukaemia with GPC-100April 15, 2025 | pharmabiz.comPExicure, Inc. (Nasdaq: XCUR) Nears Completion of Phase 2 Study of GPC-100 in Multiple MyelomaApril 14, 2025 | businesswire.comExicure, Inc. (Nasdaq: XCUR) Announces Their Next Step in Planning for a New Clinical Trial in ...April 11, 2025 | gurufocus.comExicure, Inc. (Nasdaq: XCUR) Announces Their Next Step in Planning for a New Clinical Trial in Acute Myeloid Leukemia (AML)April 11, 2025 | investing.comExicure, Inc. (Nasdaq: XCUR) Announces Their Next Step in Planning for a New Clinical Trial in Acute Myeloid Leukemia (AML)April 11, 2025 | businesswire.comWednesday’s Insider Moves: Top Buys and Sells in US StocksMarch 27, 2025 | investing.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeMTVA, PRLD, XCUR, and KALA Company DescriptionsKALA BIO NASDAQ:KALA$7.38 +0.22 (+3.07%) Closing price 08/8/2025 04:00 PM EasternExtended Trading$7.33 -0.05 (-0.73%) As of 08/8/2025 05:33 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.KALA BIO, Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of innovative therapies for rare and severe eye diseases in the United States. The company's product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects. Its preclinical development product, including KPI-014 for the treatment of rare inherited retinal diseases. The company was formerly known as Kala Pharmaceuticals, Inc. and changed its name to KALA BIO, Inc. in August 2023. KALA BIO, Inc. was incorporated in 2009 and is headquartered in Arlington, Massachusetts.MetaVia NASDAQ:MTVA$0.63 -0.01 (-1.01%) As of 08/8/2025 04:00 PM EasternMetaVia Inc. is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. MetaVia Inc., formerly known as NeuroBo Pharmaceuticals Inc., is based in CAMBRIDGE, Mass.Prelude Therapeutics NASDAQ:PRLD$0.86 +0.00 (+0.06%) Closing price 08/8/2025 04:00 PM EasternExtended Trading$0.86 0.00 (-0.06%) As of 08/8/2025 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Prelude Therapeutics Incorporated, a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT1419, a myeloid cell leukemia-1 inhibitor, which is in Phase 1 clinical trial for the treatment of selected relapsed/refractory myeloid or B-cell malignancies; PRT2527, a cyclin-dependent kinase, which is in Phase 1 clinical trial for the treatment of advanced solid tumors; PRT3645, a cyclin-dependent kinase 4/6 inhibitor, which is in Phase 1 clinical trial for the treatment of advanced and metastatic solid tumors; and PRT3879, a SMARCA2 selective protein degrader, which is in Phase 2/3 clinical trial for the treatment of advanced and metastatic solid tumors with loss of SMARCA4 due to truncating mutation and/or deletion. The company's CDK9 program is a regulator of cancer-promoting transcriptional programs, including MCL1, MYC and MYB. Prelude Therapeutics Incorporated was incorporated in 2016 and is based in Wilmington, Delaware.Exicure NASDAQ:XCUR$7.45 +0.09 (+1.22%) Closing price 08/8/2025 03:57 PM EasternExtended Trading$7.41 -0.04 (-0.54%) As of 08/8/2025 07:26 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Exicure, Inc., an early-stage biotechnology company, develops nucleic acid therapies targeting ribonucleic acid against validated targets. The company's preclinical candidate includes SCN9A that is in preclinical studies for the treatment of chronic pain. It also develops immuno-oncology therapeutics based on its proprietary SNA technology. Exicure, Inc. was founded in 2011 and is headquartered in Chicago, Illinois. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Airbnb Beats Earnings, But the Growth Story Is Losing Altitude Dutch Bros Just Flipped the Script With a Massive Earnings Beat Amazon Takes an Equity Stake in IonQ—Any Upside Potential? D-Wave Delivers Growth Shock—Investors Eye Quantum Future Is Eli Lilly’s 14% Post-Earnings Slide a Buy-the-Dip Opportunity? Constellation Energy’s Earnings Beat Signals a New Era AppLovin’s Q2 Miss Spooks Market, But Wall Street Doubles Down DraftKings Posts Record Quarter, Eyes Profitability Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
